scPharmaceuticals Inc. (SCPH)
SCPH Stock Price Chart
Explore scPharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze SCPH price movements and trends.
SCPH Company Profile
Discover essential business fundamentals and corporate details for scPharmaceuticals Inc. (SCPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Nov 2017
Employees
162.00
CEO
John H. Tucker
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
SCPH Financial Timeline
Browse a chronological timeline of scPharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 17 Mar 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.25.
Earnings released on 7 Aug 2025
EPS came in at -$0.34 falling short of the estimated -$0.30 by -13.33%, while revenue for the quarter reached $16.04M , missing expectations by -21.56%.
Earnings released on 14 May 2025
EPS came in at -$0.34 falling short of the estimated -$0.27 by -25.93%, while revenue for the quarter reached $11.75M , missing expectations by -25.78%.
Earnings released on 19 Mar 2025
EPS came in at -$0.35 surpassing the estimated -$0.40 by +12.50%, while revenue for the quarter reached $12.15M , missing expectations by -9.55%.
Earnings released on 13 Nov 2024
EPS came in at -$0.37 falling short of the estimated -$0.30 by -23.33%, while revenue for the quarter reached $10.03M , missing expectations by -17.65%.
Earnings released on 14 Aug 2024
EPS came in at -$0.44 matching the estimated -$0.44, while revenue for the quarter reached $8.05M , beating expectations by +1.05%.
Earnings released on 14 May 2024
EPS came in at -$0.36 surpassing the estimated -$0.45 by +20.00%, while revenue for the quarter reached $6.10M , beating expectations by +2.04%.
Earnings released on 13 Mar 2024
EPS came in at -$0.35 surpassing the estimated -$0.42 by +16.67%, while revenue for the quarter reached $6.10M , beating expectations by +10.43%.
Earnings released on 8 Nov 2023
EPS came in at -$0.41 falling short of the estimated -$0.36 by -13.89%, while revenue for the quarter reached $3.80M , missing expectations by -28.65%.
Earnings released on 10 Aug 2023
EPS came in at -$0.36 surpassing the estimated -$0.37 by +2.70%, while revenue for the quarter reached $1.64M , beating expectations by +1.11%.
Earnings released on 10 May 2023
EPS came in at -$0.30 surpassing the estimated -$0.36 by +16.67%, while revenue for the quarter reached $2.06M , beating expectations by +17.89%.
Earnings released on 22 Mar 2023
EPS came in at -$0.30 surpassing the estimated -$0.42 by +28.57%.
Earnings released on 9 Nov 2022
EPS came in at -$0.37 surpassing the estimated -$0.41 by +9.76%.
Earnings released on 9 Aug 2022
EPS came in at -$0.35 falling short of the estimated -$0.32 by -9.37%.
Earnings released on 16 May 2022
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%.
Earnings released on 22 Mar 2022
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%.
Earnings released on 9 Nov 2021
EPS came in at -$0.24 surpassing the estimated -$0.32 by +25.00%.
Earnings released on 11 Aug 2021
EPS came in at -$0.26 surpassing the estimated -$0.30 by +13.33%.
Earnings released on 12 May 2021
EPS came in at -$0.26 surpassing the estimated -$0.31 by +16.13%.
Earnings released on 23 Mar 2021
EPS came in at -$0.28 surpassing the estimated -$0.36 by +22.22%.
Earnings released on 16 Nov 2020
EPS came in at -$0.33 surpassing the estimated -$0.38 by +13.16%.
SCPH Stock Performance
Access detailed SCPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.